Compare ALZN & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALZN | VVOS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.5M |
| IPO Year | 2021 | 2020 |
| Metric | ALZN | VVOS |
|---|---|---|
| Price | $1.31 | $0.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $28.00 | $2.75 |
| AVG Volume (30 Days) | 105.9K | ★ 322.5K |
| Earning Date | 03-11-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.77 | 6.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,443,000.00 |
| Revenue This Year | N/A | $69.66 |
| Revenue Next Year | N/A | $48.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.05 |
| 52 Week Low | $0.84 | $0.36 |
| 52 Week High | $2.68 | $5.69 |
| Indicator | ALZN | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 41.97 |
| Support Level | $1.04 | $0.38 |
| Resistance Level | $2.25 | $0.55 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 85.94 | 50.56 |
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.